Bill > HB1275

This bill aims to ensure that human stem cell therapies in Georgia are used ethically to improve patient outcomes, specifically by prohibiting the use of stem cells derived from aborted fetuses. It defines key terms like "FDA" (United States Food and Drug Administration), "human stem cell therapy," and "Wharton's jelly" (a type of stem cell from umbilical cords), and clarifies that "minimally manipulated" refers to processing that doesn't significantly alter the original characteristics of cells or tissues. Under this bill, physicians, or designated physician assistants or nurse practitioners, can perform stem cell therapies not yet approved by the FDA, provided the patient is fully informed and signs a consent form detailing the treatment, its unapproved status, and expected results. These therapies must use stem cells sourced from facilities registered with the FDA and located in Georgia, another U.S. state, or another country, or from facilities certified by recognized accrediting bodies like the National Marrow Donor Program. Facilities must also notify physicians of any changes to their certification status, and all therapies must adhere to federal manufacturing practices. Advertisements for these unapproved therapies must include a clear notice advising patients to consult their primary care provider. Exceptions are made for physicians operating under FDA approval for investigational drugs or devices, or those working for accredited institutions. Violations of these provisions can lead to disciplinary action against the licensed professional.

Health and Social Services

https://www.legis.ga.gov/legislation/73116